CD30+ anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features

Blood

Volumn 96, Issue 12, 2000, Pages 3681-3695

  Stein, H ^a   Foss, H D ^a   Durkop, H ^a   Marafioti, T ^a   Delsol, G ^a   Pulford, K ^a   Pileri, S ^a   Falini, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

B CELL LYMPHOMA; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE REARRANGEMENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

GENE REARRANGEMENT; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL, KI-1; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 0034554843     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. The expression of the Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
2. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy
3. Ki-1 positive large cell lymphoma: A morphologic and immunologic study of 19 cases
4. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: Diagnostic value in so-called malignant histiocytosis
5. Primary and secondary cutaneous Ki-1 + (CD30+) anaplastic large cell lymphomas: Morphologic, immunohistologic, and clinical characteristics
6. Anaplastic large cell Ki-1 lymphoma: Delineation of two morphological types
7. Ki-1-positive large cell lymphoma: A clinicopathologic study of 41 cases
8. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes)
9. The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma
10. Diffuse large cell lymphomas of B and T cell type
11. Small-cell-predominant variant of primary Ki-1 (CD30) + T-cell lymphoma
12. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype
13. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
14. Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma
15. CD30+ anaplastic large-cell lymphoma, null type, with signetring appearance
16. Primary systemic anaplastic large cell lymphoma (ALCL)
17. Anaplastic large cell lymphoma and its morphological variants
18. The interface of Hodgkin's disease and anaplastic large cell lymphoma
19. Diagnosis of Hodgkin's disease, Hodgkin's like anaplastic large cell lymphoma, and T cell/histiocyte-rich B cell lymphoma
20. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma')
21. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis
22. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35
23. Morphology in Ki-1 (CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35)
24. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells
25. Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly-detected small-cell population
26. Activation antigens: New and previously defined clusters
27. BER-H2: A new monoclonal antibody of the Ki-1 family for detection of Hodgkin's disease in formaldehyde-fixed tissue sections
28. CD30(Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy
29. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines
30. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
31. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
32. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. 1. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay
33. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines
34. Variable expression of leucocyte-common antigen (CD45) in CD30 (Ki-1)-positive anaplastic large cell lymphomas: Implications for the differential diagnosis between lymphoid and non-lymphoid malignancies
35. Genotypic analysis of large cell lymphomas which express the Ki-1 antigen
36. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules
37. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma
38. World Health Organization classification of lymphomas: A work in progress
39. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
40. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: Pathological and clinical features
41. Sarcomatoid variant of anaplastic large cell lymphoma
42. Anaplastic large cell malignant lymphoma with extensive eosinophilic or neutrophilic infiltration
43. Ki-1-positive anaplastic large cell lymphoma can mimic benign dermatoses
44. Cutaneous involvement by neutrophil rich, CD30-positive anaplastic large cell lymphoma mimicking deep pustules
45. Signet ring cell of T-cell type with CD30 expression
46. The distinction of Hodgkin's disease from anaplastic large cell lymphoma
47. Ki-1-anaplastic large cell lymphoma: Is it a discrete entity?
48. Frequent expression of the B-cell-specific activator protein in Reed-Steinberg cells of classical Hodgkins's disease provides further evidence for its B-cell origin
49. Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms: Morphologic, immunophenotypic, genotypic and clinical features of 24 cases
50. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: Evidence for distinct cellular origin
51. The expression of TIA-1 + cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): Correlation with morphology, immunophenotype, ultrastructure, and clinical features
52. Cell specificity of granzyme gene expression
53. Granzymes: Exogenous proteinases that induce target cell apoptosis
54. Cultured human NK cells express the Ki-1/CD30 antigen
55. Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among Japanese
56. Anaplastic large cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas
57. The t(2,5)-associated p80 NPM-ALK fusion protein in nodal and cutaneous lymphoproliferative disorders
58. Characterisation of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations
59. NPM-ALK expression as a diagnostic marker in cutaneous CD30-positive T-cell lymphoproliferative disorders
60. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: A clinicopathologic study of 65 cases
61. Anaplastic large cell lymphoma (CD30 +/Ki-1 +): Results of a prospective clinico-pathological study of 69 cases
62. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma)
63. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
64. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease
65. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease
66. ALK expression defines a distinct group of T/null lymphomas ('ALK lymphomas') with a wide morphological spectrum
67. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease
68. A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation
69. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas
70. Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma: Dissociation between phenotype and genotype
71. Large-cell hematolymphoid neoplasms of uncertain lineage
72. Most of CD30+ anaplastic large cell lymphoma of B cell type show somatic mutation in the IgH V region genes
73. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
74. Isolation and characterization of the human nucleophosmin/B23 (NPM) gene: Identification of the YY1 binding site at the 5' enhancer region
75. Proteins C23 and B23 are the major nucleolar silver staining proteins
76. Nucleolar localization of protein B23 (37/5.1) by immunocytochemical techniques
77. Major nucleolar proteins shuttle between nucleus and cytoplasm
78. Formation of nucleophosmin/B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein
79. Nucleolar targeting signal of Rex protein of human T-cell leukemia virus type I specifically binds to nucleolar shuttle protein B-23
80. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
81. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase
82. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
83. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
84. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma
85. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)
86. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity
87. Retrovirus-mediated gene ALCL transfer of NPM-ALK causes lymphoid malignancy in mice
88. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat fibroblasts
89. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas
90. Analysis of the t(2;5)(p23;q35) translocation by reverse-transcriptase polymerase chain reaction in CD30+ anaplastic large cell lymphoma, in other non-Hodgkin's lymphomas of T cell phenotype and in Hodgkin's disease
91. Low frequency of association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients: Reverse-transcriptase polymerase chain reaction studies
92. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions
93. Molecular detection of the (2;5) translocation of non-Hodgkin lymphomas by reverse-transcriptase polymerase chain reaction
94. The t(2,5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin
95. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization
96. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: Indication of a common pathogenesis?
97. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals
98. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
99. The t(2;5) or NPM-ALK translocation in lymphomas: Diagnostic considerations
100. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry
101. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining
102. Detection of normal and chimeric nucleophosmin in human cells
103. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
104. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation
105. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
106. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma
107. t(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma
108. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma
109. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
110. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
111. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas
112. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene
113. A new variant ALK-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
114. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
115. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from recurrent cryptic chromosomal inversion, inv(2)(p23q35)
116. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: Two cases expressing ALK kinase fused to CTLC (clathrin chain polypeptide-like)
117. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation
118. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors
119. Expression of the ALK tyrosine kinase gene in neuroblastoma
120. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type
121. Low incidence of Epstein-Barr virus presence in primary cutaneous T-cell lymphoproliferations
122. CD30-positive anaplastic large cell lymphoma in childhood: Expression of p80npm/alk and absence of Epstein-Barr virus
123. Expression of carbohydrate antigens, p80NPM/ALK, cytotoxic cell-associated antigens, and Epstein-Barr virus gene products in anaplastic large cell lymphomas
124. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: Unexpected infection patterns and different infection incidence in low- and high-grade types
125. Clinicopathologic, immunological and genetic studies of CD30+ anaplastic large cell lymphoma of B-cell type: Association with Epstein-Barr virus in a Japanese population
126. HIV-associated malignant lymphomas in Kenya (Equatorial Africa)
127. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
128. Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center
129. Childhood non-Hodgkin lymphomas in the United Kingdom: Findings from the UK Children's Cancer Study Group
130. ALK+ lymphoma: Clinico-pathological findings and outcome
131. Bone marrow involvement in anaplastic large cell lymphoma
132. Anaplastic large cell lymphomas expressing the chimeric protein p80 NPM/ALK: A distinct clinicopathologic entity
133. Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood
134. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies
135. Pediatric lymphomas: Recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood
136. Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients
137. Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome
138. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: Sequential intensive treatment with F-MACHOP regimen (+ radiotherapy) and autologous bone marrow transplantation
139. Bone marrow transplantation for childhood Ki-1 lymphoma
140. Antitumor reactivity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large cell lymphoma
141. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation
142. Ribosome-mediated cleavage of the NPM-ALK transcript coding for a chimeric tyrosine kinase associated with anaplastic large cell lymphoma
143. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease
144. EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphoma study group of the European Organisation for the Research and Treatment of Cancer
145. CD30/Ki-1-positive lymphoproliferative disorders of the skin - Clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group
146. Prognostic significance of CD30 (Ki-Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients
147. Primary CD30+ cutaneous lymphomas (including lymphomatoid papulosis)
148. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant
149. CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: The first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus-related systemic lymphomas
150. Transformation of cutaneous T cell lymphoma to large cell lymphoma: A clinicopathologic and immunologic study
151. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma
152. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients
153. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large cell lymphoma